Effects of a Patient Portal Intervention to Address Diabetes Care Gaps
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the effect of a novel patient portal intervention on the number of patients with diabetes care gaps (e.g., no diabetes eye exam i the last 12 months). The intervention is designed to: (a) notify patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allow patients to initiate orders for the care.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Participants will be recruited from 14 VUMC-affiliate adult primary care clinics located throughout Middle Tennessee. Patients will be randomized 1:1 to the intervention or usual care. 500 adult patients with type 1 or 2 diabetes mellitus will be assigned to one of two arms. 250 will be assigned to receive access to the intervention embedded within an existing patient web portal (My Health at Vanderbilt) at Vanderbilt University Medical Center. 250 will be assigned to a usual care comparison arm with access to the currently available version of My Health at Vanderbilt without the study intervention. At enrollment, participants will complete a baseline questionnaire and diabetes health data will be abstracted from the patients' electronic health record (EHR) before being assigned to the intervention or control arm. Participants will receive additional follow-up questionnaires and diabetes health data will be abstracted from the EHR at 3-month, 6-month, and 12-month follow-ups to assess outcomes. In addition, system usage data (user analytics) will be collected throughout the study period.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention Patients have access to an existing patient web portal (My Health at Vanderbilt) embedded with the Diabetes Care Gaps Patient Portal Intervention. . |
Other: Diabetes Care Gaps Patient Portal Intervention
The Diabetes Care Gaps Patient Portal Intervention is embedded within an existing patient web portal (My Health at Vanderbilt). The intervention (a) notifies patients when selected, clinically meaningful, evidence-based diabetes monitoring & preventative care (e.g., annual urine microalbumin) are due and (b) allows patients to initiate orders for the care.
|
| No Intervention: Usual Care Patients will have access to an existing patient web portal (My Health at Vanderbilt) NOT embedded with the intervention (i.e., usual care). |
Outcome Measures
Primary Outcome Measures
- Number of Diabetes Care Gaps at 6 months [6-month follow-up]
Number of diabetes care gaps per patient out of four possible: no diabetes eye exam in the last 12 months, no hemoglobin A1C blood test in the last 6 months, no urine microalbumin in the last 12 months, and no pneumovax vaccination (PPSV-23) despite existing indication The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction.
Secondary Outcome Measures
- Number of Diabetes Care Gaps [Baseline, 3-month follow-up, and 12-month follow-up]
Number of diabetes care gaps per patient out of four possible: no diabetes eye exam in the last 12 months, no hemoglobin A1C blood test in the last 6 months, no urine microalbumin in the last 12 months, and no pneumovax vaccination (PPSV-23) despite existing indication The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction
- Proportion of patients with no diabetes Care Gaps [Baseline, 3-month follow-up, 6-month follow-up and 12-month follow-up]
Proportion of patients who are up-to-date (i.e., no care gaps) on all four selected DM monitoring and preventative services: diabetes eye exam in the last 12 months, hemoglobin A1C blood test in the last 6 months, urine microalbumin in the last 12 months, and pneumovax vaccination (PPSV-23) despite existing indication The presence of a diabetes care gap will be assessed by electronic health record (EHR) abstraction.
- Patient Initiated Orders [Baseline, 3-month follow-up, 6-month follow-up, and 12-month follow-up]
The number of patient-initiated orders for evidence-based diabetes monitoring and preventative services (e.g., A1c).
- Order Completion [Baseline, 3-month follow-up, 6-month follow-up, and 12-month follow-up]
The number of completed (i.e., care received) patient-initiated orders for evidence-based diabetes monitoring and preventative services.
- Understanding of Diabetes Monitoring and Preventative Care [Baseline, 3-months, 6-months, and 12-months]
Unique study specific items (four items) to assess participant's understanding of measures of diabetes monitoring and preventative care (e.g., Diabetes Eye Exams) will be administered to all study participants. Each multiple-choice item has only one correct answer and the overall measure is scored as the percent of the items answered correctly.
- Change in Self-Efficacy to Manage Diabetes [Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up]
The 5-item Manage Disease in General Scale of the Chronic Disease Self-Efficacy Scales is a validated measure of self-efficacy (i.e., the confidence a person has in managing their own health and health care) and is closely related to patient activation. The items were adapted to be specific to diabetes rather than a generic condition or illness. Each item uses a 10-point Likert-type scale of response options ranging from 1 (not at all confident) to 10 (totally confident). Responses result in total raw scores ranging from 5 to 50. The score for the scale is the mean of the items. Higher scores indicate greater self-efficacy.
- Change in Diabetes Distress [Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up]
The Problem Areas in Diabetes Scale (PAID-5) is a valid measure of diabetes distress. The PAID-5 contains 5 items which have a five-point response option (0-4 representing 'Not a problem' through to 'Serious problem'). Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress care (e.g., Diabetes Eye Exams) will be administered to all study participants.
- Satisfaction/Usability of My Health at Vanderbilt (for control group) and Study Intervention (for intervention group) [Baseline, 3-month follow-up, 6-month follow-up, and 12-month follow-up]
The System Usability Scale (SUS) is a valid measure of usability and assesses user's perceptions of ease of use, likability of the interface, and overall satisfaction. Each question on the 10-item questionnaire is scored on a 5-point Likert scale [0 (Strongly disagree) to 4 (strongly agree)] and the sum is totaled (0-40). The total sum is then multiplied by 2.5 to convert the original scores to a range of 0 (worst) to 100 (best). Based on prior research, a score above 68 would be above average and a score of 85 or above suggests excellent usability. The SUS has been used in several studies of patient facing health information technology (the article describing its psychometric properties has been cited over 500 times) and has excellent internal consistency reliability (Cronbach's alpha of 0.91).
- Change in Blood Glucose Control [Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up]
Participants' most recent hemoglobin A1C will be abstracted from participants' electronic medical record.
- Treatment Intensification [Baseline to 3-month follow-up, baseline to 6-month follow-up, and baseline to 12-month follow-up]
The addition or increase in dose of: (a) antihyperglycemic medications and (b) antihypertensive medications will be assessed by EHR abstraction.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Established patient with a participating primary care physician from a participating clinic
-
Type 1 or 2 diabetes mellitus
-
Able to read in English
-
Age 18 to 75 years old
-
Mobile device (smartphone or tablet) with internet access
-
Active My Health at Vanderbilt (MHAV) account
Exclusion Criteria:
-
A medical condition that prevents use of a mobile device
-
Pregnant or planning to become pregnant during the study period
-
Severe difficulty seeing
-
On dialysis
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Vanderbilt University Medical Center | Nashville | Tennessee | United States | 37212 |
Sponsors and Collaborators
- Vanderbilt University Medical Center
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
- Principal Investigator: William Martinez, MD, MS, Vanderbilt University Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 212257
- R18DK123373